anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Survivors randomized to webMFT will receive the evidence-based intervention for moderate-to-vigorous physical activity (MVPA) promotion that consists of MVPA counseling matched to patients' motivational readiness, and self-monitoring of MVPA (via Fitbit Inspire 2). The goal for the 3-month program will be to gradually increase the amount of moderate-intensity aerobic exercise that is performed, to the current national recommendations of at least 150 minutes of MPVA per week. Our goal is to promote aerobic exercise that is safe and enjoyable, such as walking.
Exercise training is a potent means of improving cardiovascular (CV) risk; however, exercise is challenging for many patient populations. Passive heat therapy may provide a simple and effective alternative to exercise for improving CV health, and no one has yet studied the physiological benefits of chronic heat exposure in humans. Heat exposure induces the expression of heat shock proteins, which can have a multitude of beneficial effects on the CV system, many of which are common to exercise training. In particular, these benefits include upregulation of many cellular pathways associated with improved vascular function, a predominant contributor to CV health. The goal of the study is to determine the effects of chronic passive heat therapy on vascular function in young, healthy, able-bodied individuals. The investigators will perform a randomized-controlled trial in which subjects participate in 8 weeks of either heat therapy or thermoneutral water immersion (sham). Heat therapy will entail 8 weeks of hot water immersion sufficient to raise core temperature \>38.5°C for 1h, 4-5 times per week. Thermoneutral water immersion will entail 8 weeks of immersion in 36°C water for the same duration as heat therapy. In both subject groups, the investigators will measure various well-established biomarkers of vascular function before and after 8 weeks of heat therapy, including measures of arterial stiffness (arterial compliance, beta-stiffness, and pulse wave velocity), endothelium-dependent dilation (flow-mediated dilation), and intima media thickness. The investigators will investigate the effects of heat therapy on the microvasculature and on the mechanisms behind improvements in vascular function in the cutaneous microcirculation, an ideal site for pharmacodissecting the molecular pathways involved, using microdialysis paired with laser-Doppler flowmetry. If successful, these studies will serve as a basis for developing heat therapy as a novel means of improving CV risk, which has the potential to reshape the treatment of patient populations with limited exercise capabilities.
Oxycodone HCl Controlled-Release Tablets contain oxycodone which is a full mu-agonist opioid with an abuse liability similar to morphine and is a Schedule II controlled substance. Oxycodone, like morphine and other opioids used in analgesia, can be abused and is subject to criminal diversion.

Drug addiction is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. There is a potential for drug addiction to develop following exposure to opioids, including oxycodone. Drug addiction is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common. 

“Drug-seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. 

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Oxycodone HCl Controlled-Release Tablets, like other opioids, have been diverted for non-medical use. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised. 

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. 

Oxycodone HCl Controlled-Release Tablets consist of a dual-polymer matrix, intended for oral use only. Abuse of the crushed tablet poses a hazard of overdose and death. This risk is increased with concurrent abuse of alcohol and other substances. With parenteral abuse, the tablet excipients, especially talc, can be expected to result in local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
Sickle cell anemia (SCA), a hereditary hemoglobinopathy, is characterized by the presence of abnormal hemoglobin and has long been associated with a wide range of complications. While much attention has been given to the condition hematological aspects, gastrointestinal complications, particularly diarrhea, have been relatively understudied and often overlooked. This publication delves into the management of gastrointestinal challenges, with a focus on diarrhea, in individuals living with SCA. The pathophysiology of SCA is intrinsically linked to gastrointestinal complications, and diarrhea is a common manifestation of this condition. This abstract publication outlines the key elements discussed in the full-length work, which includes the clinical presentation of diarrhea in these patients, the diagnostic tools used to evaluate the condition, and various management strategies to alleviate symptoms and enhance the overall quality of life for affected individuals. The paper emphasizes the importance of patient education, offering healthcare professionals valuable insights into how to inform and support patients in managing their conditions effectively. It also highlights the need for continued research to further our understanding of gastrointestinal challenges in SCA and to identify potential areas for future therapeutic interventions. Ultimately, the comprehensive management of diarrhea in individuals with SCA is vital for their overall well-being. This publication serves as a valuable resource for healthcare providers, researchers, and caregivers in addressing the gastrointestinal challenges that accompany SCA, ultimately working toward a better quality of life for those affected by this condition.
Postmarketing cases of hepatitis, including fulminant hepatitis progressing to liver failure requiring transplantation or resulting in death, have been reported in patients treated with EFV. Reports have included patients with underlying hepatic disease, including coinfection with hepatitis B or C, and patients without pre-existing hepatic disease or other identifiable risk factors.

EFV, a component of SYMFI LO, is not recommended for patients with moderate or severe hepatic impairment. Careful monitoring is recommended for patients with mild hepatic impairment receiving EFV [see Adverse Reactions (6.1) and Use in Specific Populations (8.7)].

Monitoring of liver enzymes before and during treatment is recommended for all patients [see Dosage and Administration (2.1)]. Consider discontinuing SYMFI LO in patients with persistent elevations of serum transaminases to greater than five times the upper limit of the normal range.

Discontinue SYMFI LO if elevation of serum transaminases is accompanied by clinical signs or symptoms of hepatitis or hepatic decompensation.
Experiencing multiple types of traumatic events can increase the risk of developing somatic and posttraumatic stress symptoms (PTSS). Medically unexplained symptoms (MUS), or somatic symptoms that lack a distinct medical explanation, often coexist with PTSS in emerging adults and may be due to common underlying mechanisms. Coping strategies have been associated with PTSS, but have not been studied in trauma-exposed individuals with MUS. The current study examined the relationship between the number of types of potentially traumatic events experienced and MUS among emerging adults, considering the influence of PTSS and engagement and disengagement coping. A sample of 363 emerging adults (Mean = 18.91) completed self-report measures of trauma history, PTSS, MUS, experiences with healthcare providers, and coping strategies. Dissatisfaction with healthcare providers was reported by 11.3% of participants reporting MUS, with over half (52.8%) feeling their concerns were dismissed. Hierarchical linear regression showed that the number of types of traumatic events experienced did not predict MUS after accounting for PTSS. Moderation hypotheses linking traumatic events and coping strategies were not supported. Results suggest that PTSS explains the relationship between exposure to different traumatic events and MUS. Findings may have diagnostic and treatment implications for healthcare providers working with emerging adults who have experienced trauma.
BACKGROUND: Oroantral fistula (OAF) involves pathological, epithelialized, and unnatural communication between the maxillary sinus and oral cavity. Recently, functional endoscopic sinus surgery has provided minimally invasive treatment options with fewer postoperative complications. The aim of the study was to evaluate the one-stage endoscopic middle meatal antrostomy (EMMA) technique with the application of a platelet-rich fibrin membrane (PRF) for OAF closure and maxillary sinusitis relief.
PATIENTS AND METHODS: Patients who suffered from OAF with odontogenic sinusitis were included in this study. Complete excision of the epithelial tract and any necrotic tissue was performed with proper curettage. Then, EMMA was performed with simultaneous closure of the OAF by the application of PRF membranes that were fixed by sutures and covered with an acrylic splint. Patients were clinically evaluated for OAF closure, pain level, and symptom relief. Additionally, the size of the bone defect was measured with the aid of computed tomography (CT) preoperatively and after 24 weeks postoperatively.
RESULTS: This study included nine eligible patients with a mean age of 38 years. The data were collected, tabulated, and statistically analyzed. Soft tissue healing and bone formation occurred in all patients who achieved maxillary sinusitis relief without any complications. Additionally, pain was significantly lower on the 7th postoperative day than on the 1st postoperative day, according to the statistical analysis of the results (p < .001).
CONCLUSIONS: One-stage EMMA with the application of PRF membranes and acrylic splint represents a reliable alternative technique for OAF closure and maxillary sinusitis relief that is associated with a lower incidence of complications and minimal postoperative pain.
TRIAL REGISTRATION: The trial was registered on 28/02/2024, at clinicaltrials.gov (ID: NCT06281873).
The invention belongs to the technical field of algorithm acceleration, and particularly provides an FPGA hardware acceleration technical method based on cell tracking. According to the invention, the multicellular is accurately detected and tracked through a cell tracking algorithm, and an FPGA-based hardware structure is used for replacing an algorithm structure in a deep learning module, so that the running speed of the algorithm is improved, and the burden of deep learning equipment is reduced. By implementing the key parts of the tracking algorithm on the FPGA, such as sampling and repeated convolution, the running speed and parallel processing capacity of the algorithm can be greatly improved. Meanwhile, the FPGA hardware acceleration can also reduce power consumption and system delay, and improve the overall performance of the system. The tracking algorithm and the FPGA hardware acceleration method provided by the invention can realize rapid and accurate tracking of large-scale cell populations, and provide powerful support for biomedical research. In addition, the method can be applied to other fields needing to efficiently process large-scale data, such as image processing, video monitoring and the like.
PURPOSE: To obtain a shampoo compsn. for hair conditioning having product stability for a long period of time and superior cleaning characteristics and imparting unexpectedly superior general conditioning properties to human's hair, especially superior suitability to wet- and dry-stage combing. CONSTITUTION: This shampoo compsn. contains an anionic surfactant, a water- soluble cationic conditioning compd. which is preferably a polymer, a water- insoluble liq. conditioning compd. having about <20 cP viscosity at 25 deg.C, a specific gravity of <1.0, preferably about <0.95 and a refractive index of at least about 1.4 at 25 deg.C and a suspending agent for the water-insoluble conditioning compd. in a proper vehicle. The water-insoluble conditioning agent is effectively deposited on hair so as to remarkably improve suitability to dry-stage combing and lubricity that are not practically improved by the water-soluble cationic conditioning agent.
Diabetes affects approximately one in 10 individuals in the United States and is associated with cardiovascular disease, nerve and retinal damage, and kidney disease. In 2019, it was reported to be the 7th leading cause of death nationally. Unfortunately, diabetes disproportionally affects people of color, those of heavier weight, and those with lower incomes. All of these characteristics are common in residents of the communities served by Montefiore Bronx Health Collective (BHC). Enrolling patients in care at BHC with prediabetes or overt diabetes into Fresh Takes! has the potential to improve short term outcomes and reduce the risk of developing diabetes-associated comorbidities for a highly vulnerable population. The 6-month program has three major components: 1) receipt of a fresh food box twice each month, 2) group nutrition education provided at the time of bimonthly food pickup, and 3) individualized support by a dietician. One of the unique aspects of Fresh Takes! is the provision of a fresh food box to participants. Healthier dietary patterns have been found to be associated with significantly lower risk of developing diabetes and better glycemic control among individuals with diabetes. Yet, little research to date has been conducted on the impact of providing fresh fruits and vegetables on diabetic control for individuals with diabetes or prediabetes.

As an exploratory assessment, following a protocol amendment submitted and approved by the IRB, to determine whether extra education and support is helpful for patients in using all of the contents of the food box, a sub-study was embedded into the existing study by providing an information intervention. As part of this sub-study, all cohort participants will receive individual assessment, education, and a food demonstration and recipe using the contents of the box. Each cohort participant will then be randomized to receive one of the following interventions: 1. Instructions to cut and store vegetables or 2. Instructions to cutting \& storing vegetables+ additional recipes customized to the contents of the food box. A block randomization approach to randomize participants to receive the intervention will be used. To avoid contamination, the package will be placed within food delivery packages. This sub-substudy will not impact any of the Outcome Measures in this study.
Participants will be in three groups- those with lower extremity DVT, those with PE, or those with both lower extremity DVT and PE. Patients will have blood drawn for thrombin generation assay, thromboelastography assay, and thromboinflammatory panel in addition to standard of care labs for diagnosis of VTE and management of anticoagulation. The patients will then fill out questionnaires on quality of life and level of exercise at their first outpatient visit 4 weeks after diagnosis. At approximately 3-6 months after diagnosis, patients will undergo two days of testing for the research study. All patients will have exercise testing using bicycle ergometry to measure global aerobic fitness. They will once again fill out questionnaires about their quality of life and level of physical activity. After a 24 hour rest period, DVT patients will undergo 31P-MR Spectroscopy and non-invasive spin labeling MRI to provide data on skeletal muscle bioenergetics (phosphocreatine metabolism), and lymphatic and venous flow respectively in the affected leg compared to the unaffected leg. This will allow each patient to be his or her own control. After these research procedures, patients will continue to receive standard of care treatment for their VTE in the Bleeding and Thrombosis clinic.
Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
PURPOSE: An extract of Acer mono Max. having antioxidative activity and a method for producing flavan compounds using the same extract are provided. The extract of Acer mono Max. has improved antioxidative activity, so that it can be added into medicines, food additives, cosmetics, beverages and health foods. CONSTITUTION: The extract of Acer mono Max. having improved antioxidative activity is produced by extracting Acer mono Max. and/or its sap with lower alcohol and with further organic solvent, preferably ethylacetate. The method for producing 3',4',5,7-tetrahydroxyflavan-3-ol of formula(1) comprises the steps of: extracting Acer mono Max. and/or its sap with lower alcohol and with further organic solvent, preferably ethylacetate; and subjecting the extract of Acer mono Max to at least one of adsorption chromatography, high pressure liquid chromatography and gas chromatography.
FuturabondU® (FBU) apply in enamel and dentin as etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15s in dentin and 30s in enamel) and then rinse with water for 1 min. Dry off excess moisture with a gentle stream of air. Activating FBU SingleDose. FBU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 20s.
PROBLEM TO BE SOLVED: To prepare the subject suppressant, comprising an extract of Phellodendri Cortex or Coptidis Rhizoma as an active ingredient, capable of specifically suppressing the synthesis of a heat shock protein group in a cell of a tissue manifesting a morbid state and effective in treating cancer, etc. SOLUTION: This suppressant for the synthesis of a heat shock protein comprises a berberine derivative of the formula (R<1> and R<2> are each a 1-3C alkyl) or its pharmaceutically permissible salt as an active ingredient and has a molecular weight between 16 and 40 kDa. Furthermore, an extract obtained by extracting, e.g. Phellodendri Cortex (a tree bark after removing the periderm from Phellodendron amurense Rupr., etc.) or Coptidis Rhizoma (a rhizome after removing most of the roots from Coptis japonica Makino) with water or an organic solvent (e.g. methyl alcohol) at a temperature below the boiling point for about 10min to 60hr by the thermal refluxing, etc., is preferably used and the daily dose thereof is usually preferably about 1mg to 10g for an adult expressed in terms of the berberine derivative administered in one to several divided portions.
Chlamydia spp. are strictly intracellular pathogens that grow inside a vacuole, called an inclusion. They possess genes encoding proteins homologous to components of type III secretion machineries which, in other bacterial pathogens, are involved in delivery of bacterial proteins within or through the membrane of eukaryotic host cells. Inc proteins are chlamydial proteins that are associated with the membrane of the inclusion and are characterized by the presence of a large hydrophobic domain in their amino acid sequence. To investigate whether some Chlamydia proteins, especially Inc proteins and other proteins exhibiting a similar hydropathic profile, might be secreted, the inventors used an heterologous secretion system, namely a type III system. Chimeras were constructed by fusing the N-terminal part of these proteins with a reporter, the Cya protein of Bordetella pertussis, and expressed in various strains of Shigella flexneri. The inventors demonstrate that these hybrid proteins are secreted by the type III secretion system of S. flexneri. Moreover, the inventors show that three other proteins from C. pneumoniae, all of which have in common the presence of a large hydrophobic domain, are also secreted by S. flexneri type III secretion machinery.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellently preventing and improving effect on chapped skin, bettering effect on hair touch, etc. by making the composition include a specific amide derivative. SOLUTION: This composition comprises an amide derivative of the formula (R1 is a 1-39C hydrocarbon; R2 is a 1-12C bifunctional hydrocarbon; R3 is a 2-12C bifunctional hydrocarbon; and R4 is a 2-6C hydroxyalkyl). The composition is obtained by reacting a compound containing two eliminable groups with preferably >=2 equivalent amine by heating preferably at 40-100 deg.C to give an intermediate and reacting the intermediate with a carboxylic acid halide (e.g. a carboxylic acid chloride, etc.), preferably in the presence of a base except the intermediate in a mixed solvent of water and an organic solvent at pH 9-14 to give the amide derivative. The amount of the amide derivative formulated in the composition is preferably 0.001-50 wt.% based on the total composition in the case of an emulsion type external preparation for skin and a skin cosmetic.
The invention belongs to the technical field of medicines, and particularly relates to a diosgenin/gefitinib composition and a preparation method thereof, and application of the composition in treating lung cancer. The active ingredients of the pharmaceutical composition comprise targeted drugs (gefitinib) and active components of traditional Chinese medicines (diosgenin). The invention uses lung cancer cells to evaluate the anti-tumor activity of the drug combination on tumor cell proliferation, metastasis and the like. Experiments prove that the combined use of gefitinib and diosgenin can synergistically inhibit activities such as lung cancer cell proliferation, and the dosage of gefitinib is greatly reduced, and the side effects of the gefitinib and the diosgenin can be correspondingly reduced. Meanwhile, experiments prove that when gefitinib and diosgenin are combined in a certain proportion range (100:1-0.01:1), the lung cancer cell transfer activity is synergistically inhibited. Therefore, the gefitinib and the diosgenin combined compatibility has good inhibition effect on the proliferation and the metastasis of lung cancer cells, and the gefitinib and the diosgenin composition can be used as effective components or formulas to prepare medicines for preventing and treating human lung cancer.